Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Pharma
Intra-Cellular's unstoppable Caplyta nails another trial
The atypical antipsychotic medication Caplyta has been on a roll, with yet another positive late-stage trial now in the bag.
Angus Liu
Nov 5, 2024 10:15am
BMS partner Zai Lab eyes China filing for KarXT after trial win
Oct 29, 2024 1:59pm
Cycle's 2nd hostile takeover bid in 5 months rejected by Vanda
Oct 14, 2024 3:18pm
BMS' schizophrenia gem Cobenfy was salvaged from the scrapheap
Oct 7, 2024 3:00am
BMS wins FDA approval for new schizophrenia med Cobenfy
Sep 26, 2024 7:38pm
Intra-Cellular closing in on major depression nod for Caplyta
Jun 18, 2024 11:40am
